1Krishnarao TV,Galgiani JN.Comparison of the in vitro activities of the echinocandin LY303366 , the pneumocandin MK -0991 , and fluconazole against Candida species and Cryptococcus neoformans[].Antimicrobial Agents and Chemotherapy.1997
2Powles MA,Liberator P,Anderson J,et al.Efficacy of MK-0991(L-743, 872 ), a semisyntheic pneumocandin, in murine models of Pneumocystis carinii[].Antimicrobial Agents and Chemotherapy.1998
3Kohler S,Wheat LJ,Connolly P,et al.Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model[].Antimicrobial Agents and Chemotherapy.2000
4Pfaller MA,Marco F,Messer SA,et al.In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 872 ),against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi[].Diagnostic Microbiology and Infectious Disease.1998
5Arikan S,Lozano-Chiu M,Paetznick V,et al.In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates[].Antimicrobial Agents and Chemotherapy.2001
6Hoang A.Caspofungin acetate: an antifungal agent[].American Journal of Health System Pharmacy.2001
7Espinel-Ingroff A.Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK -0991 ( L -743 , 872 ) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts[].Journal of Clinical Microbiology.1998
8Ripeau JS,Aumont F,Belhumeur P,et al.Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro[].Antimicrobial Agents and Chemotherapy.2002
9Franzot SP,Casadevall A.Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro[].Antimicrobial Agents and Chemotherapy.1997
10Arathoon EG,Gotuzzo E,Noriega LM,et al.Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases[].Antimicrobial Agents and Chemotherapy.2002
3Bachmann SP, VandeWalle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms [J]. Antimicrob Agents Chemother, 2002,46( 11 ) : 3 591.
4Cocuaud C, Rodier MH, Daniault G, et al. Anti-metabolic activity of caspofungin against Candida albicans and Can- dida parapsilosis biofilms[J]. J Antimicrob Chemother, 2005,56(3) :507.
5Cateau E, Rodier MH, Imbert C. In vitro efficacies of ea- spofungin or micafungin catheter lock solutions on Candi- da albicans biofilm growth[J]. J Antimicrob Chemother, 2008,62( 1 ) : 153.
6Tobudic S, Lassnigg A, Kratzer C, et al. Antifungal acti- vity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature de- velopment phases[J]. Mycoses, 2010,53 (3) : 208.
7Ramage G, VandeWalle K, Wickes BL, et al. Standard- ized method for in vitro antifungal susceptibility testing of Candida albieans biofilms[J]. Antimicrob Agents Che- mother, 2001,45(9) : 2 475.
8Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations[J]. Antimicrob Agents Chemoth- er, 2004,48(9 ) : 3 407.
9Melo AS, Colombo AL, Arthington-Skaggs BA. Paradox- ical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species[J]. Antimicrob Agents Chemother, 2007,51 (9) : 3 081.
10Graybill JR,Najiar LK,Montalbo EM,et al.Treament of histoplasmosis with MK-991(L-743,872)[J].Antimicrob Agents Chemther,1998,42(1):151-153.
